Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2023: Technologies, Biomarker Cargo & Diagnostics

Gerardo Kaplan's Biography

Gerardo Kaplan, Principal Investigator, FDA

Dr. Kaplan received a Doctoral Degree in Biology from the University of Buenos Aires, Argentina. As a Postdoctoral Fellow at Columbia University, NYC, he studied different aspects of poliovirus (PV) biology including mapping the first IRES that conferred cap-independent translation, developing the first subgenomic replicons, and selecting PVR neutralization-resistant mutants to understand the PV-PVR interaction. In the early 90s, Dr. Kaplan joined the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) as a tenure-track investigator. At CBER, he discovered the hepatitis A virus (HAV) cellular receptor 14, the first identified member of a family of molecules that modulate asthmatic, autoimmune, and graft-versus-host disease, anti-viral, and anti-cancer immune responses. He was tenured at CBER in 1998 due to his contributions to the HAV filed and regulatory work leading to the licensing of HAV vaccines. From 2001 to 2008, he served as the Chief of the Laboratory of Hepatitis and Related Emerging Agents at the Office of Blood Research and Review (OBRR), CBER. At OBRR, his work contributed to the identification of members of the HAVCR family (also referred as TIM family) as pattern recognition receptors (PRR) of phosphatidylserine, showed that the interaction of HAV with HAVCR1 on regulatory T cells (Treg) blocks T-cell receptors, shuts off Treg function, and controls the pathogenic process of HAV7. In response to the FDA need to gain expertise in bioterrorism agents, Dr. Kaplan developed a filovirus program focused on vaccines based on the viral glycoprotein (GP) and BSL2 tests to evaluate anti-GP total and neutralizing antibodies. Dr. Kaplan is currently a Principal Investigator at the Lab of Molecular Virology, CBER-FDA and an Affiliated Faculty at George Mason University. He continuous working in pathogenesis of HAV and the role of HAVCR1 in cell entry of viruses and exosomes.

Gerardo Kaplan Image

Exosome Mimicry in Virus Infection: The Hepatitis A Virus Model

Wednesday, 26 July 2023 at 20:30

Add to Calendar ▼2023-07-26 20:30:002023-07-26 21:30:00Europe/LondonExosome Mimicry in Virus Infection: The Hepatitis A Virus ModelExtracellular Vesicles 2023: Technologies, Biomarker Cargo and Diagnostics in Orlando, FloridaOrlando,

Hepatitis A virus (HAV), a small positive-strand RNA non-enveloped virus, uses the exosome secretory machinery to exit the cell. Although HAV is mainly transmitted through the fecal-oral route by naked particles, infectious exosomes (exo-HAV) carrying HAV particles, free genomes, or both are found in blood. We showed that exo-HAV uses the HAVCR1/NPC1 pathway of exosome mimicry to infect cells, and that the cargo of free HAV genomes but not naked particles are mainly responsible for infectivity. We also showed that cargo loading into exo-HAV during infection is a dynamic process resulting in exosomes lacking naked HAV particles. Further research on the HAV exosome mimicry model will help unravel poorly understood exosome cargo-delivery pathways, develop therapeutics to prevent and treat HAV infection, and harness HAV biology to produce exosome-based drugs.

Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonExtracellular Vesicles 2023: Technologies, Biomarker Cargo and DiagnosticsExtracellular Vesicles 2023: Technologies, Biomarker Cargo and Diagnostics in Orlando, FloridaOrlando,